Introduction {#Sec1}
============

Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic inflammation of synovial joints \[[@CR1], [@CR2]\]. The persistence of intra-articular inflammation causes cartilage destruction and bone erosion, leading to peripheral joint deformation and disability. Joint damage and functional loss are present at the very early stages, but the rate of progression of disease varies among individual patients \[[@CR3], [@CR4]\].

The global prevalence of RA in the adult population is estimated to be 0.5--1%; however, it appears to depend greatly on the geographical area (Japan 0.2%, Netherlands 1--1.5%, Scandinavian Peninsula 3%, Spain 0.5%, and United States 1%) \[[@CR5], [@CR6]\]. In Italy, two observational studies estimated a prevalence of 0.33% in Liguria and 0.31% in Lombardy \[[@CR5], [@CR7]\]. Despite its relatively low prevalence, RA is associated with significant disability and high economic and social impact \[[@CR8]\]. Conventional disease-modifying anti-rheumatic drugs (cDMARDs), such as methotrexate (MTX), represent the first-line of treatment, whereas biologic disease-modifying anti-rheumatic drugs (bDMARDs) constitute second-line strategy and are recommended in all patients with inadequate response or who are intolerant, or for whom it would be inappropriate to continue treatment with cDMARDs \[[@CR9], [@CR10]\].

The use of bDMARDs has brought significant progress in RA therapy as they allow a very high proportion of patients to achieve clinical remission or low disease activity, with a concomitant reduction of long-term disability \[[@CR11]--[@CR15]\]. In most cases, bDMARDs---including adalimumab (ADA), abatacept, infliximab, etanercept (ETN), certolizumab (CTZ), golimumab, rituximab, and tocilizumab (TCZ)---are administered in combination with MTX for the treatment of moderate to severe RA in adult patients with an inadequate response to MTX. In other cases, some of these agents (ADA, ETN, CTZ, and TCZ) can be used as monotherapy in the treatment of RA patients who are intolerant to MTX, or for whom it is inappropriate to continue treatment with MTX.

By focusing attention on this latter therapeutic indication, the aim of this analysis was to estimate the efficacy and treatment costs of monotherapy with bDMARDs in treatment of RA patients who are intolerant to MTX, or for whom it is inappropriate to continue MTX treatment.

Methods {#Sec2}
=======

Clinical Data {#Sec3}
-------------

The main criteria for evaluating improvement or clinical response to pharmacological treatment for RA are those recommended by the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR). Both these societies have reached consensus regarding the minimum number of active disease variables (core set) to be measured to evaluate the efficacy of treatment \[[@CR16]\]. These variables include: number of painful and swollen joints, measurement of residual functional abilities, serological evaluation of acute phase reactants (erythrocyte sedimentation rate \[ESR\] and C-reactive protein \[CRP\]), and opinion of disease activity expressed by both the doctor and patient, in addition to that on the intensity of pain perceived by the patient \[[@CR17]\]. EULAR criteria are based on absolute values and on changes in the disease activity score (DAS)/DAS28 compared to baseline (assessment and classify response to treatment as good, moderate, or absent) \[[@CR18]\]. ACR criteria evaluate the improvement (20%, 50%, 70%) in all core set variables \[[@CR16]\]. Despite being different, both criteria are used routinely in clinical trials.

The present economic analysis is based on two meta-analyses that focused on the efficacy of bDMARD monotherapy for the treatment of RA \[[@CR19], [@CR20]\]. The first, carried out by Orme et al. \[[@CR20]\] using the main medical databases (Medline, Embase, and Cochrane Library), considered all randomized phase 2 and 3 clinical studies on the treatment of patients with RA using ACR (ACR 20, 50, and 70) criteria as the clinical endpoint. In line with the main objective of the present analysis, Table [1](#Tab1){ref-type="table"} shows the details of the estimated efficacy data (vs. placebo) for the bDMARDs used in monotherapy.Table 1ACR 20, 50, and 70: bDMARDs monotherapy vs. placebo \[[@CR20]\]TreatmentsACR 20ACR 50ACR 70Placebo14.1% (11.1%, 17.7%)5.9% (3.9%, 8.7%)1.3% (0.6%, 3.1%)ADA 40 mg/EOW44.8% (32.4%, 57.9%)23.2% (12.5%, 39.8%)13.2% (3.6%, 42.8%)ETN 2 × 25 mg/week66% (45.6%, 83.4%)46.4% (21.3%, 78.1%)20.9% (3.3%, 92%)TCZ 8 mg/kg/4 weeks81.1% (61%, 92.8%)74.7% (31.2%, 98.3%)43% (5.4%, 98.9%)*ACR* American College of Rheumatology, *ADA* adalimumab, *bDMARDs* biologic disease-modifying anti-rheumatic drugs, *EOW* every other week, *ETN* etanercept, *TCZ* tocilizumab

The second meta-analysis, which is a "final appraisal determination" from the UK National Institute for Health and Care Excellence (NICE) \[[@CR19]\], available online, evaluated the efficacy of bDMARDs in the treatment of treatment-naive patients with RA or those who failed previous treatment with cDMARDs using EULAR criteria. The efficacy results (vs. placebo) are shown in Table [2](#Tab2){ref-type="table"} and refer to biologics used as monotherapy \[[@CR19]\].Table 2EULAR criteria: bDMARD monotherapy vs. placebo \[[@CR19]\]TreatmentsModerate responseGood responsePlacebo50% (7%, 94%)12% (5%, 65%)ADA 40 mg/EOW76% (33%, 98%)31% (5%, 78%)ETN 2 × 25 mg/week71% (12%, 99%)26% (1%, 87%)TCZ 8 mg/kg/4 weeks93% (77%, 99%)61% (32%, 88%)*ADA* adalimumab, *bDMARDs* biologic disease-modifying anti-rheumatic drugs, *EOW* every other week, *ETN* etanercept, *EULAR* European League Against Rheumatism, *TCZ* tocilizumab

Both meta-analyses are identified TCZ as the most efficacious monotherapy in the treatment of patients who are intolerant to MTX, or for whom it would be inappropriate to continue treatment with MTX \[[@CR19], [@CR20]\].

Number Needed to Treat {#Sec4}
----------------------

Methodological progresses have led to the development of instruments specific to the field of pharmacoeconomic evaluation, with the final aim to calculate the incremental cost-effectiveness ratio (ICER). This indicator allows decision-makers to know at what additional cost it is possible to purchase an additional unit of result, expressed in the form of quality-adjusted life years (QALY). Once the ICER per QALY has been calculated, to verify its acceptability, it must be compared with a reference "threshold value", which according to AIES (Associazione Italiana di Economia Sanitaria) guidelines, should be €40,000 \[[@CR21]\]. It is important to remember that the purpose of this threshold which is calculated considering quality-adjusted or unadjusted survival as its outcome is to express the decision-maker's willingness to pay to obtain an additional unit of health (QALY).

In this specific case, the two meta-analyses considered \[[@CR19], [@CR20]\] did not provide, among the various outcomes evaluated, any results in terms of simple life years (LY) or QALY. Thus, an incremental analysis approach can be applied, since it would not have been possible to calculate an ICER per life year gained to be compared with the reference threshold value; however, it would have been possible to determine an ICER for an 'intermediate' outcome (e.g., ICER per patient at the therapeutic target), but that cannot be compared with the reference threshold value \[[@CR21]\].

To overcome the problem of finding a result indicator without being able to evaluate its quality, it was decided to perform a pharmacoeconomic comparison between bDMARDs with the aim of estimating the respective cost for the number needed to treat (NNT) compared to placebo \[[@CR22], [@CR23]\]. This indicator represents the number of patients to be treated to obtain a given therapeutic benefit, or in this case the number of patients that has to be treated with a specific bDMARD compared to placebo to obtain a responder, in which efficacy is measured using both ACR and EULAR criteria. Hence, by multiplying this indicator by the relative cost of treatment, the cost of NNT associated with the bDMARDs can be calculated.

Time Horizon and Perspective {#Sec5}
----------------------------

When comparing two or more healthcare technologies for pharmacoeconomic purposes, national \[[@CR21]\] and international guidelines \[[@CR25], [@CR26]\] recommend the use of a time horizon suited to understand all the main differences expressed in terms of both outcomes and treatment costs. Given that in the majority of the clinical studies considered in the two meta-analyses, the median follow-up efficacy period was 24 weeks; it was decided that for this analysis, a 6-month period would be adequate to understand the most important differences in efficacy and treatment costs.

The economic analysis was conducted from a National Health Service (NHS) perspective.

bDMARDs {#Sec6}
-------

As mentioned above, the aim of this analysis was to explore the efficacy and treatment costs of bDMARDs with an authorized indication as monotherapy for patients who are intolerant to MTX, or for whom it is inappropriate to continue treatment with MTX. In Italy, there are currently four bDMARDs with this indication: ADA, ETN, CTZ, and TCZ. The first three, administered via a subcutaneous (sc) route, are tumor necrosis factor (TNF)-α inhibitors, while the fourth, administered via both the sc and intravenous (iv) routes, is an inhibitor of the interleukin-6 (IL-6) receptor \[[@CR19]\].

The two meta-analyses only provided efficacy data for three of the four bDMARDs: ADA, ETA, and TCZ. For this reason, CTZ was excluded from the base case analysis and considered only in the sensitivity analysis (see relevant paragraph in *Sensitivity Analysis* section). On the basis of the results of the SUMMACTA study, which demonstrated that TCZ sc (162 mg injection a week) and TCZ iv (8 mg/kg every 4 weeks) have comparable efficacy, the two meta-analyses did not distinguish between the two formulations \[[@CR24]\].

Treatment Cost {#Sec7}
--------------

Direct medical costs, such as pharmacological therapy (bDMARDs), administration and monitoring were only considered. Other direct medical costs (i.e., adverse events) were excluded since they were assumed similar to all bDMARDs considered.

Table [3](#Tab3){ref-type="table"} indicates the mean 6-month cost of the monotherapies included in the comparison. The per pack cost of the bDMARDs is the ex-factory price including the temporary discounts imposed by national law (AIFA Resolution of 3 July 2006, Official Gazette N. 156 of 7 July 2006, and subsequent AIFA Resolution of 9 February 2007, Official Gazette N. 57 of 9 March 2007 and extensions thereof), excluding any other discounts agreed with NHS facilities. These costs were calculated considering the doses indicated in the respective Summaries of Product Characteristics.Table 3Mean 6-month cost of treatment with bDMARD monotherapybDMARDsDosePackPack priceMonthly cost6-month costTocilizumab (iv)^a^Every 4 weeks8 mg/kg€149.25€1131.77€6790.65Tocilizumab (sc)1 syr OW4 syr 162 mg€1044.17€1131.19€6787.13Etanercept (sc)50 mg OW4 syr 50 mg€969.49€1050.29€6301.71Adalimumab (sc)40 mg EOW2 syr 40 mg€1015.13€1099.73€6598.36Certolizumab (sc)200 mg EOW2 syr 200 mg€920.55€997.26€5983.58*bDMARDs* biologic disease-modifying anti-rheumatic drugs, *EOW* every other week, *iv* intravenous, *OW* once a week, *sc* subcutaneous, *syr* syringe^a^Assuming an average patient weight of 70 kg

In line with the procedures implemented in Italy, the cost of administration was considered only for the bDMARDs administered intravenously, whereas no cost was assumed for sc drugs. The charge applied for an iv infusion was considered to be €11.62, as indicated by the national list of charges for specialist outpatient healthcare services \[[@CR27]\].

The healthcare resource consumption associated with monitoring activities was calculated using the data indicated in a recent national experience comparing TCZ iv with ADA sc \[[@CR28]\]. Table [4](#Tab4){ref-type="table"} indicates the healthcare resource consumption and mean costs for monitoring activities, making a distinction between sc and iv regimens, for the 6-month observation period. Healthcare services were calculated using the corresponding NHS charges \[[@CR27]\]. The cost of 6 months of monitoring associated with an iv bDMARD was almost three times that estimated for sc bDMARD (€270.46 vs. €100.48).Table 4Monitoring: mean 6-month costs \[[@CR28]\]Healthcare servicesUnit costbDMARDs IVbDMARDs SC6-month service6-month cost6-month service6-month costVisit€20.666€123.962€41.32Complete blood count€3.176€19.022€6.34ESR and CRP€5.826€34.922€11.64Hepatic function€2.046€12.242€4.08Urea, electrolytes, and creatinine€9.576€57.422€19.14Chest X-ray€15.491€15.491€15.49Cholesterol€2.473€7.411€2.47Total (6 months)€270.46€100.48*bDMARDs* biologic disease-modifying anti-rheumatic drugs, *CRP* C-reactive protein, *ESR* erythrocyte sedimentation rate, *IV* intravenous, *SC* subcutaneous

Sensitivity Analysis {#Sec8}
--------------------

The sensitivity analysis was carried out with the aim of evaluating the degree of uncertainty of the results of the base case \[[@CR29]\]. It focused on the key variables of the analysis, i.e., the efficacy data obtained from the two meta-analyses, which made it possible to determine the mean cost for the NNT for the biologics considered. A first part of the sensitivity analysis was conducted by simultaneously varying each efficacy parameter to observe its effect on the mean cost per NNT, considering first the lower and then the upper limit of the respective variability range.

In a second phase, to obtain data on the use of CTZ monotherapy, the base case results were recalculated, replacing the ACR response rates estimated by Orme et al. \[[@CR20]\] with those obtained in another meta-analysis, whose objectives also included estimating the efficacy of monotherapy in patients who are intolerant to MTX, or for whom it is inappropriate to continue treatment with MTX \[[@CR30]\]. In that meta-analysis, a specific efficacy value (ACR 20, 50, and 70) was calculated for TCZ and a mean value was calculated for TNF-α inhibitors among which CTZ was considered, in addition to ETA and ADA. For the latter, an overall 6-month cost of €6084.06 was considered. In line with the methods adopted for the other biologics, the cost was composed of €100.48 for monitoring and €5983.58 for purchase of the biologic (Table [3](#Tab3){ref-type="table"}). For the sc bDMARDs, no cost was considered for administration.

Sensitivity analysis on monitoring and administration costs was not performed as they have a minimal impact on overall costs, and therefore, even significant changes in the base values would not have produced any differences that would substantially affect the base case results. For different reasons, sensitivity analysis for the cost of pharmacological treatment was not carried out. In the base case, the purchase cost net of compulsory legal discounts and gross of any other discounts granted to hospital facilities was used. As this latter type of discount is hard to quantify, it was preferred to not consider alternative scenarios to the base case, which undoubtedly would not have reflected the actual situation.

Compliance with Ethics Guidelines {#Sec9}
---------------------------------

This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.

Results {#Sec10}
=======

NNT (Efficacy) {#Sec11}
--------------

Table [5](#Tab5){ref-type="table"} shows two separate series of NNT for TCZ (iv/sc), ADA, and ETA. The first series was calculated using ACR criteria, while EULAR criteria were used for the second. In both cases, TCZ (iv/sc) had a lower NNT (higher efficacy) than the other agents. The difference in the values observed for ETN was more pronounced using EULAR criteria, whereas in the comparison with ADA, the most sensitive differences were observed with ACR criteria.Table 5NNTNNT vs. placeboTCZ (iv)TCZ (sc)ETN (sc)ADA (sc)ACR criteria ACR 201.491.491.933.26 ACR 501.451.452.475.78 ACR 702.402.405.108.40EULAR criteria Moderate response2.332.334.763.85 Good response2.042.047.145.26*ACR* American College of Rheumatology, *ADA* adalimumab, *ETN* etanercept, *EULAR* European League Against Rheumatism, *iv* intravenous, *sc* subcutaneous, *TCZ* tocilizumab

Cost of Treatment {#Sec12}
-----------------

Table [6](#Tab6){ref-type="table"} shows the mean 6-month cost per treated patient, which is the sum of the ex-factory drug price plus the costs of administration and monitoring (these last two expense items only have a minimal impact on the overall cost (range 1.5--4.8%). ETN had the lowest treatment cost (€6402.19), followed by ADA (€6698.84), TCZ sc (€6887.61), and TCZ iv (€7130.83). The differences compared to ETN vary from a minimum of approximately €300 (vs. ADA) to a maximum of about €700 (vs. TCZ iv).Table 6Mean 6-month costs of treatment per patientCostsTCZ (iv)TCZ (sc)ETN (sc)ADA (sc)Administration€69.72€0.00€0.00€0.00Monitoring€270.46€100.48€100.48€100.48Medicinal product€6790.65€6787.13€6301.71€6598.36Total€7130.83€6887.61€6402.19€6698.84*ADA* adalimumab, *ETN* etanercept, *iv* intravenous, *sc* subcutaneous, *TCZ* tocilizumab

Cost for NNT {#Sec13}
------------

Figures [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"} show the mean cost per NNT calculated using ACR or EULAR response criteria. In terms of the percentage of patients achieving ACR response (20, 50, or 70), TCZ sc had the lowest cost for NNT. Despite having higher administration and monitoring costs, iv TCZ showed lower mean costs for the NNT than ETN or ADA. The greater the clinical improvement according to ACR (20, 50, or 70) criteria, the greater the cost for the NNT calculated for TCZ (sc/iv) and the cost calculated for ETN or ADA. The mean cost for NNT calculated using EULAR response criteria showed that TCZ sc was the best treatment option, followed by TCZ iv. The differences compared to ETN and ADA were significant and related with the level of efficacy.Fig. 1Mean cost for the NNT: ACR criteria. *ACR* American College of Rheumatology, *ADA* adalimumab, *ETN* etanercept, *NNT* number needed to treat, *iv* intravenous, *sc* subcutaneous, *TCZ* tocilizumabFig. 2Mean cost for the NNT: EULAR criteria. *ACR* American College of Rheumatology, *ADA* adalimumab, *ETN* etanercept, *EULAR* European League Against Rheumatism, *NNT* number needed to treat, *iv* intravenous, *sc* subcutaneous, *TCZ* tocilizumab

Sensitivity Analysis {#Sec14}
--------------------

Table [7](#Tab7){ref-type="table"} shows the results of the sensitivity analysis carried out in the light of changes in efficacy rates in relation to the limits of the corresponding variability ranges. In almost all comparisons, TCZ was associated with the lowest mean costs for NNT, with the exception of the case considering the upper limit of the confidence interval for the EULAR criteria, where ETN appeared to be the most cost-effective option. Table [8](#Tab8){ref-type="table"} shows the results of the sensitivity analysis using efficacy data of the meta-analysis conducted by Buckley et al. \[[@CR29]\]. In this comparison, TCZ (sc/iv) had the lowest mean cost for NNT. The cost-effectiveness of TCZ was also confirmed compared to CTZ, which was the biologic with the lowest treatment costs in the six-month observation period.Table 7Sensitivity analysis (efficacy data variation) \[[@CR19], [@CR20]\]Criteria for the NNTTCZ (iv)TCZ (sc)ETN (sc)ADA (sc)ACR criteria ACR lower limit€14,261.66€13,775.22€18,566.35€31,417.56 ACR 20 upper limit€9484.00€9160.52€9731.33€16,680.11 ACR 50 lower limit€26,098.84€25,208.65€36,812.59€77,907.51 ACR 50 upper limit€7986.53€7714.12€9219.15€21,570.26 ACR 70 lower limit€148,535.19€143,468.92€237,137.12€223,272.34 ACR 70 upper limit€7416.06€7163.11€7170.45€16,881.08EULAR criteria Moderate response lower limit€10,197.09€9849.28€128,043.80€25,790.53 Moderate response upper limit€142,616.60€137,752.20€128,043.80€167,471.00 Good response lower limit€23,032.58€22,246.98N/AN/A Good response upper limit€31,019.11€29,961.10€29,129.96€51,514.08*ACR* American College of Rheumatology, *ADA* adalimumab, *ETN* etanercept, *EULAR* European League Against Rheumatism, *N/A* not applicable, *NNT* number needed to treat, *iv* intravenous, *sc* subcutaneous, *TCZ* tocilizumabTable 8Sensitivity analysis (Buckley et al. \[[@CR29]\])PlaceboTCZ (iv)TCZ (sc)ETN (sc)ADA (sc)CTZ (sc)Efficacy ACR 2017.30%72.90%72.90%58.30%58.30%58.30% ACR 506.20%50.50%50.50%30.50%30.50%30.50% ACR 701.30%28.80%28.80%15.50%15.50%15.50%NNT (calculated compared to placebo) ACR 20N/A1.81.82.442.442.44 ACR 50N/A2.262.264.124.124.12 ACR 70N/A3.643.647.047.047.04Cost for the NNT ACR 20N/A€12,835.49€12,397.70€15,621.34€16,345.17€14,845.11 ACR 50N/A€16,115.68€15,566.00€26,377.02€27,599.22€25,066.33 ACR 70N/A€25,956.22€25,070.90€45,071.42€47,159.83€42,831.78*ACR* American College of Rheumatology, *ADA* adalimumab, *CTZ* certolizumab, *ETN* etanercept, *N/A* not applicable, *NNT* number needed to treat, *iv* intravenous, *sc* subcutaneous, *TCZ* tocilizumab

Discussion {#Sec15}
==========

The present analysis used the NNT as a synthetic indicator to assess the clinical benefits and costs associated with the use of different monotherapies (ADA, ETA, CTZ, and TCZ) in the treatment of patients who are intolerant to MTX, or for whom it is no longer appropriate to continue therapy with MTX. The NNT was calculated using both ACR response rates, indicated in the meta-analysis conducted by Orme et al. \[[@CR20]\], and EULAR criteria, obtained from the meta-analysis conducted by NICE in its recent appraisal \[[@CR19]\]. For each bDMARD, we calculated the respective 6-month costs for purchase, administration, and monitoring by the NHS.

TCZ had the lowest mean cost for the NNT calculated with both response criteria, which were slightly higher for the iv formulation after administration and monitoring. The costs calculated for the other sc bDMARDs were significantly higher. Hence, it was seen that the greater the clinical improvement, according to ACR (20, 50, or 70) or EULAR criteria (moderate or good response), the greater the difference in NNT costs in favor of TCZ (sc/iv).

While it is worthwhile to discuss the results of economic analysis by comparing them with those already published, to the best of our knowledge there are no other similar assessments in this specific patient population. However, three cost-utility analyses that estimated the incremental cost per QALY for TCZ compared to other TNF-α inhibitors are available. In the first study, carried out in Greece, TCZ had an incremental cost per QALY of €28,837 compared to the use of other TNF-α inhibitors in the treatment of patients intolerant to MTX or for whom it was not appropriate to continue treatment with MTX \[[@CR31]\]. The second analysis, carried out in the United States, compared monotherapy with TCZ or ADA for the treatment of patients with RA for whom treatment with MTX was not appropriate \[[@CR32]\]. The authors, on the basis of the results of the ADACTA direct comparison clinical study, calculated an incremental cost per QALY of US \$36,944 in favor of TCZ compared with ADA. The third study \[[@CR33]\], from the UK, evaluated the cost-utility of TCZ in addition to the current sequence of treatments envisaged for RA. In that report, two scenarios were explored: one for patients for whom MTX is contraindicated and one for tolerant patients. For each of these scenarios, three different treatment strategies were compared: (1) standard of care (consisting a sequence of the most commonly administered biologics), (2) TCZ as first-line therapy, and (3) TCZ as second-line therapy. In patients for whom MTX is contraindicated, TCZ was found to be cost-effective as both first- and second-line therapy, whereas in MTX-tolerant patients the strategy involving the addition of TCZ (first- or second-line) was found to be similar to that determined by the standard of care. All three analyses concluded that TCZ was a cost-effective option in patients with RA for whom biologic monotherapy was indicated, thus confirming the results of the present analysis with different methods.

To analyze the limits of our study, as previously mentioned the two meta-analyses considered did not allow determination of clinical outcomes expressed in terms of survival simple or QALY, essentially changing the choice of assessment method to the cost for the NNT as an indicator of cost-effectiveness. For this reason, we compared the bDMARDs by calculating the number of subjects needed to be treated to achieve a specific therapeutic target (ACR/EULAR). With this indicator, it was possible to determine an order of preference among the bDMARDs based on cost-effectiveness.

A further aspect that needs to be discussed is the efficacy data used to calculate the NNT. Although the two meta-analyses \[[@CR19], [@CR20]\] evaluated a large number of randomized clinical studies, the efficacy data are characterized by a broad range of variability. Given this uncertainty, sensitivity analysis was required to evaluate its impact on the final results. It was also seen that by simultaneously considering the upper or lower extremities of the efficacy rate variability range (ACR 20, 50, 70, moderate or good response), the results of the base case were more or less confirmed. Additionally, as confirmation of the clinical data used herein, a subsequent analysis conducted versus alternative monotherapies (ADA, ETA, CTZ) showed that TCZ had a greater likelihood of being the most effective treatment in inducing ACR 20, 50, and 70 responses \[[@CR34]\].

Hence, it must be pointed out that the efficacy of TCZ, as mentioned in both meta-analyses, must be interpreted with a caution given the direct effect that the agent has on CRP values, as the latter is a component of the ACR and EULAR composite endpoints on which the comparison was based. To confirm the validity of the results of the meta-analyses, it is important to remember that in some of the most recent clinical studies investigating the efficacy of TCZ monotherapy (ACT-RAY and ADACTA studies) that the composite endpoints were calculated using ESR values only. This avoids potential bias due to CRP values, but at the same time confirmed the greater efficacy of TCZ \[[@CR35], [@CR36]\]. Hence, a post hoc analysis of the ADACTA study \[[@CR36]\], which used the Clinical Disease Activity Index (CDAI) criterion (a parameter that does not consider values such as CRP or ESR to evaluate disease activity and remission rates), also confirmed the efficacy of TCZ, in agreement with the findings obtained in the ADACTA study \[[@CR35]\].

Given the limited effect on total costs, no sensitivity analysis was conducted for monitoring and administration of drugs. To allow homogeneous comparison for the biologic agents, the cost considered was the NHS purchase cost net of compulsory legal discounts only. Because it is difficult to identify the actual drug cost that takes into account all the discounts granted to hospital structures, it was considered unreasonable to conduct sensitivity analysis on this parameter.

As this economic analysis was conducted from the Italian NHS perspective, the present results may not be directly generalized to other countries with different drug costs and healthcare services reimbursement. Furthermore, the analysis considered only the economic impact of a few direct medical costs (drugs, administration, and monitoring).

Conclusions {#Sec16}
===========

The results of the present economic assessment, estimating the mean costs of NNT showed that TCZ represents a cost-effective therapeutic option in an NHS perspective compared to other TNF-α inhibitors (ADA, ETA, CTZ) as first-line monotherapy for patients who are intolerant to MTX, or for whom it is inappropriate to continue treatment with MTX.
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